Study Reveals How Cells Destroy Faulty Proteins In Cystic Fibrosis
Main Category: Cystic FibrosisArticle Date: 14 Aug 2006 - 22:00 PDT
| Patient / Public: | ![]() |
4.6 (5 votes) |
| Healthcare Prof: | ![]() |
5 (1 votes) |
The cellular system that degrades faulty proteins created by the cystic fibrosis gene has been identified by University of North Carolina at Chapel Hill scientists. Turning off the degradation system allows some proteins to regain their proper shape, offering a new avenue for treatments aimed at curing the disease.
Cystic fibrosis (CF) is a fatal disease caused by a defective gene that produces a misshapen form of the protein cystic fibrosis transmembrane conductance regulator (CFTR). People with cystic fibrosis do not have enough CFTR for their cells to work normally because their bodies quickly destroy the mutant protein.
"Most cases of CF are caused by the inability of faulty CFTR to get in the correct shape, which leads cells to place it in the trash bin," said senior author Dr. Douglas Cyr, professor of cell and developmental biology at UNC School of Medicine. "Our research helps define the basic mechanism for CF and identify targets for the development of therapeutics designed to get CFTR into shape and allow it function normally in the lung," Cyr said.
The results, published Aug., 2006, in the journal Cell, point to several possible targets for the development of new treatments aimed at stopping the disease, the researchers said.
Scientists have known for some time that treatment of cultured cells with compounds known as chemical chaperones can increase the fitness of misshaped CFTR and get it into proper shape. Thus, "If we can figure out how to get CFTR into the right shape, we can cure the disease," Cyr said.
To better understand how to fix CFTR, Cyr's research team at the UNC Cystic Fibrosis Pulmonary Research and Treatment Center focused on identifying the cellular system that disposes of faulty CFTR. The investigators identified cell components that specifically recognizes misshapen CFTR and drops it in the molecular trash bin. The team found that turning off these components - the cell's trash collectors -- extends the life of faulty CFTR proteins and thereby enables some of it to assume a functional shape.
The trash collectors newly identified by the Cyr group are two different ubiquitin ligases, proteins that specifically recognize misshaped regions of CFTR and tag them with a degradation signal known as ubiquitin. The ubiquitin tag tells the cell to destroy the marked CFTR, a process overseen by a destroyer called the proteasome. This trash system is known as the ubiquitin proteasome pathway.
"We've identified the trash collectors that recognize misfolded proteins, decide if they might be toxic to the cell and mark them with ubiquitin. The ubiquitinated proteins, including faulty CFTR, are then degraded or shredded by the proteasome," Cyr said.
"Understanding this pathway gives us greater insight into what's wrong with the protein -- information that will help people design better therapeutics for the disease," Cyr said.
###
Study co-authors , all from UNC Cystic Fibrosis Center, include J. Michael Younger, graduate student and first author; postdoctoral researchers Drs. Liling Chen, Meredith F.N. Rosser, Emma L. Turnbull and Chung-Yan Fan; Hong-Yu Ren, technician; and Dr. Cam Patterson, professor of medicine, cardiology division chief and director of the Carolina Cardiovascular Biology Center.
The UNC Cystic Fibrosis Pulmonary Research and Treatment Center is a multidisciplinary group focused on the pathogenesis and therapy of cystic fibrosis and other lung diseases. It has one of the largest clinical programs in the country, with more than 500 patients in the pediatric and adult programs.
This research was funded by the National Institute of General Medical Sciences, part of the National Institutes of Health, the Cystic Fibrosis Foundation and the American Heart Association.
Contact Dr. Douglas Cyr at dmcyr@med.unc.edu
Contact: L. H. Lang
University of North Carolina School of Medicine
Visit our cystic fibrosis section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/49404.php>
APA
http://www.medicalnewstoday.com/releases/49404.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



